알코올 사용 장애 시장 : 약제 클래스별, 치료 유형별, 최종사용자별, 유통 채널별, 제제별 - 세계 예측(2025-2032년)

The Alcohol Use Disorder Market is projected to grow by USD 2.17 billion at a CAGR of 6.76% by 2032.

Framing the evolving Alcohol Use Disorder treatment landscape with integrated care pathways, long-acting pharmacotherapies, and digital access models to inform strategic decisions

The landscape of Alcohol Use Disorder (AUD) care is rapidly evolving as clinical practice, pharmacologic options, and delivery models converge to better meet the growing demand for evidence-based treatment. Advances in long-acting formulations and multimodal approaches have reframed treatment conversations, while digital platforms and telehealth have expanded pathways to care. Consequently, the continuum of AUD management now emphasizes sustained recovery, individualized therapeutic combinations, and durable engagement strategies across diverse care settings.

Clinicians and health system leaders are increasingly prioritizing integrated care pathways that combine behavioral interventions with pharmacotherapy, and payers are recalibrating coverage criteria in response to outcomes data and cost-of-care considerations. Meanwhile, regulatory movements and public health campaigns are shaping perceptions and access, underscoring the importance of adaptable clinical protocols and supply-chain resilience. This introduction outlines the main forces reshaping treatment paradigms, highlights the intersection of technology and therapeutics, and situates stakeholders to capitalize on actionable insights emerging across clinical, regulatory, and commercial domains.

Navigating multipronged changes in therapy modalities, digital access pathways, payer incentives, and stigma reduction that are reshaping Alcohol Use Disorder care delivery

A series of transformative shifts is redefining how AUD is identified, treated, and managed across healthcare systems. First, therapeutic innovation has expanded beyond traditional oral dosing to include injectable long-acting agents that improve adherence and reduce relapse risk, prompting clinicians to reconsider initiation and maintenance strategies. This therapeutic diversification is accompanied by renewed emphasis on combination approaches that align behavioral therapies with pharmacotherapies to bolster both short-term engagement and long-term recovery trajectories.

Concurrently, digital health solutions are changing patient touchpoints. Telehealth and remote monitoring enable continuity of care for patients in rural or underserved areas and facilitate stepped-care models that move patients between intensity levels according to real-time clinical signals. These digital pathways also create opportunities for novel adherence interventions and remote behavioral coaching that complement in-person services. Meanwhile, payer and regulatory environments are responding to these innovations with more nuanced coverage determinations and value-based contracting pilots that prioritize measurable outcomes over service volume.

Finally, public and provider awareness campaigns have shifted stigma-related barriers to care, increasing screening rates and early intervention. Collectively, these changes generate a more patient-centric, outcomes-oriented ecosystem that rewards integrated care, device-enabled adherence, and evidence-based combinations of behavioral and pharmacologic modalities. Stakeholders who align product development, distribution, and clinical training with these shifts are positioned to lead in both clinical impact and commercial performance.

Analyzing how 2025 tariff shifts catalyzed supply chain regionalization, procurement adaptations, and manufacturing resilience for Alcohol Use Disorder therapies

United States tariff adjustments in 2025 introduced new dynamics into pharmaceutical procurement, supply chain costs, and manufacturer sourcing strategies, with cumulative consequences for AUD-related products and distribution channels. Tariff-related cost pressures compelled manufacturers to reassess manufacturing footprints and supplier contracts, prompting shifts toward regionalized sourcing and alternative raw material suppliers. These adjustments influenced lead times and inventory practices for oral tablets, effervescent formulations, and injectable therapeutics, encouraging greater reliance on buffer inventories and diversified logistics partners.

In turn, hospital pharmacies, specialty pharmacies, and retail distributors adjusted procurement cadence to mitigate exposure to pricing volatility. Some providers increased contract durations with preferred suppliers to lock in price stability, while others explored consignment and group-purchasing arrangements to preserve access without disproportionately transferring costs to patients. These procurement adaptations affected the availability of both immediate-release and sustained-release oral formulations as well as injectable intramuscular and subcutaneous options, with downstream implications for initiation protocols and adherence programs.

Additionally, the tariff environment accelerated conversations around domestic manufacturing incentives and reshored capacity for critical excipients and finished-dose forms. Policymakers and industry leaders engaged in dialogue about incentives to stabilize supply chains and reduce systemic vulnerability. As a result, strategic planning for commercialization now routinely incorporates tariff scenario modeling, dual-sourcing strategies, and cost-pass-through considerations to maintain therapeutic continuity for patients while preserving financial viability for manufacturers and distributors.

Distilling operationally relevant segmentation insights across drug classes, treatment modalities, care settings, distribution channels, and formulation strategies to guide commercialization and clinical adoption

A nuanced segmentation analysis reveals distinct opportunities and execution imperatives across drug classes, treatment modalities, care settings, distribution channels, and formulation types. Within drug classes, the market includes acamprosate, disulfiram, and naltrexone; acamprosate's effervescent and oral tablet presentations support different adherence and tolerability profiles, disulfiram is primarily deployed in oral tablet form where supervised administration and behavioral frameworks are emphasized, and naltrexone is available both as injectables and oral tablets, enabling clinicians to tailor initiation strategies based on patient adherence risk and comorbidity profiles. These distinctions inform clinical positioning and messaging that emphasize onset of effect, adherence mechanisms, and comparative tolerability.

When examining treatment types, behavioral therapy, combined therapy, and pharmacotherapy create complementary pathways for intervention. Behavioral therapy encompasses cognitive behavioral therapy, family therapy, and motivational enhancement therapy, each addressing different psychosocial drivers of substance use and recovery readiness. Combined therapy-such as cognitive behavioral therapy with pharmacotherapy or motivational enhancement therapy with pharmacotherapy-integrates pharmacologic support with structured psychosocial interventions to enhance engagement and outcomes. Pharmacotherapy itself bifurcates into injectable and oral drugs, which present divergent needs in terms of dispensing, monitoring, and reimbursement practices. Understanding the interplay between these treatment paradigms is critical for designing integrated care protocols and training programs for multidisciplinary teams.

End-user segmentation further differentiates operational requirements and access patterns. Home healthcare, hospitals, rehabilitation centers, and specialty clinics each demand tailored service models. Home healthcare services leverage home visits and telehealth to extend continuity for patients who prefer community-based care, hospitals-both private and public-serve as high-acuity initiation points where inpatient stabilization and transitioning to outpatient care are coordinated, rehabilitation centers operate across inpatient and outpatient modalities to support structured recovery programs, and specialty clinics, including alcohol rehabilitation and psychiatric clinics, focus on longitudinal follow-up and complex case management. These distinctions affect referral pathways, reimbursement mechanisms, staffing models, and the design of adherence support services.

Distribution channel segmentation highlights the importance of channel-specific strategies. Hospital pharmacies-split between private and public institutions-must balance formulary access and acute-care needs, online pharmacies accessed via e-commerce websites and mobile apps facilitate convenience and discreet delivery for maintenance therapy, retail pharmacies comprised of chain and independent outlets provide widespread dispensing capability and patient counseling touchpoints, and specialty pharmacies, both addiction-focused and general, offer medication therapy management and care coordination for complex cases. Tailoring supply chain logistics, patient education, and specialty services to these channels enhances access and retention.

Finally, formulation segmentation-dispersible tablet, effervescent tablet, injectable, and oral tablet-demands careful commercialization choices. Injectable forms include intramuscular, intravenous, and subcutaneous routes that vary in administration setting and clinical workflow, while oral tablets encompass immediate-release and sustained-release profiles that influence dosing frequency and adherence support needs. Bringing these formulation insights together enables manufacturers, payers, and providers to align product development, reimbursement strategies, and patient support programs with real-world clinical utilization patterns and operational constraints.

Comparative regional dynamics revealing payer complexity, regulatory heterogeneity, and digital-enabled access trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence treatment access, regulatory approaches, and service delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and expanding telehealth infrastructure have supported rapid adoption of combined therapy models and long-acting injectables, while diverse payer landscapes necessitate flexible reimbursement strategies and robust health economics narratives to secure formulary placement and coverage for newer modalities. Cross-border supply chains in the region also respond dynamically to tariff and logistics changes, prompting localized procurement adjustments.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and variable health system capacities create both challenges and targeted opportunities. High-income markets within this region often lead with structured national treatment guidelines and strong specialty clinic networks, supporting adoption of evidence-backed combination treatments and specialty pharmacy services. Conversely, lower-resource settings emphasize task-shifting, community-based interventions, and scalable behavioral programs, which present opportunities to leverage telehealth and simplified pharmacotherapy regimens that are easy to deploy at scale.

The Asia-Pacific region exhibits a mix of rapid urbanization, growing healthcare infrastructure investment, and distinct cultural attitudes toward substance use that shape demand and care pathways. Increasing investments in specialty clinics, expanding private hospital networks, and mobile health penetration create fertile ground for novel distribution channels such as mobile app-enabled pharmacy services and hybrid home healthcare models. Across regions, supply-chain resilience, regulatory alignment, and culturally tailored patient engagement approaches emerge as cross-cutting enablers for successful deployment of AUD therapeutics and integrated care services.

Examining company strategies that combine diversified portfolios, channel partnerships, real-world evidence generation, and supply-chain resilience to drive uptake and sustain access

Key company-level dynamics center on portfolio diversification, channel partnerships, and investments in patient support infrastructure. Leading manufacturers and specialty distributors increasingly prioritize integrated commercial models that pair product availability with adherence programs, digital monitoring tools, and clinician education to accelerate uptake and optimize outcomes. Strategic partnerships between pharmaceutical firms and specialty pharmacies or telehealth providers enable streamlined initiation processes for long-acting therapies and support continuity of care across inpatient and outpatient transitions.

Additionally, contract strategies and value-based arrangements are gaining prominence as payers seek measurable outcome improvements and cost containment. Companies that can demonstrate robust real-world evidence and offer bundled services-such as medication management, tele-coaching, and outcome tracking-are better positioned to negotiate favorable coverage terms. Supply-chain investments, including dual-sourcing, regional manufacturing partnerships, and contingency inventories, have become integral to preserving product availability and mitigating tariff-related disruptions.

Finally, companies that invest in clinician training, stigma-reduction campaigns, and culturally sensitive patient materials tend to secure stronger prescriber relationships and higher initiation rates. By aligning commercial efforts with evidence-based clinical practices and responsive distribution strategies, market participants can drive both clinical impact and sustainable business performance in a complex and rapidly evolving therapeutic area.

Prioritize supply-chain resilience, integrated pharmacotherapy and behavioral programs, and digital-enabled care while aligning payer partnerships for durable access gains

Industry leaders should adopt a dual-focus strategy that combines tactical operational resilience with long-term clinical and commercial positioning. In the near term, firms must prioritize supply-chain diversification, implementing dual-sourcing and regional manufacturing arrangements to reduce exposure to tariff-driven disruptions and ensure consistent access to oral, effervescent, and injectable formulations. At the same time, aligning procurement and inventory strategies with hospital pharmacies, specialty pharmacies, and retail partners will safeguard availability across both acute and maintenance settings.

Concurrently, organizations should invest in integrated care enablement by scaling programs that combine pharmacotherapy with evidence-based behavioral therapies. Embedding cognitive behavioral therapy, family therapy, and motivational enhancement therapy into care pathways alongside pharmacologic options encourages adherence and supports sustained recovery. Companies can accelerate adoption by funding clinician education, supporting multidisciplinary care teams, and offering reimbursement-ready value propositions grounded in real-world outcomes.

To capture long-term value, leaders must also prioritize digital engagement and home-based care models. Telehealth, mobile adherence tools, and remote monitoring expand reach and reduce barriers to care, especially when paired with specialty pharmacy support and telepharmacy services. Finally, fostering payer partnerships through transparent outcomes measurement and pilot value-based agreements will facilitate broader access; by demonstrating measurable improvements in clinical and economic endpoints, organizations can de-risk coverage decisions and create a favorable environment for innovative therapies and service bundles.

Employing a mixed-methods evidence synthesis that triangulates primary stakeholder interviews, clinical literature, regulatory signals, and scenario modeling to ensure actionable rigor

The research approach combined a mixed-methods design that integrated primary qualitative engagement with secondary synthesis of peer-reviewed literature, clinical guidelines, regulatory communications, and publicly available policy statements. Primary inputs included structured interviews with clinicians across inpatient and outpatient settings, procurement leaders at hospital and specialty pharmacies, and executives from manufacturers and distributors. These engagements provided frontline perspectives on adoption drivers, administrative barriers, and the operational implications of formulation and channel choices.

Secondary analysis synthesized clinical trial literature, guideline updates, and health system policy changes to contextualize primary insights and validate observed trends. The methodology emphasized triangulation: qualitative findings were cross-referenced with published clinical evidence and regulatory developments to strengthen analytic rigor. Scenario analysis simulated the operational impacts of supply-chain disruptions and tariff shifts, while thematic coding of interview transcripts identified recurring barriers and enablers related to initiation, adherence, and reimbursement.

Throughout, emphasis was placed on transparency and reproducibility. Data sources were documented, stakeholder selection criteria were specified to ensure representativeness across care settings and regions, and analytic steps were recorded to permit replication. This methodology supports defensible conclusions and actionable recommendations while reflecting the multifaceted realities of clinical practice, procurement, and commercialization in AUD care.

Synthesize the interplay between therapeutic innovation, delivery evolution, and operational resilience to define priorities for sustainable clinical and commercial impact

The converging trends in therapeutics, delivery channels, and policy create a decisive moment for stakeholders involved in Alcohol Use Disorder care. Innovations in formulation and integrated treatment approaches are expanding the toolkit available to clinicians, while digital platforms and evolving reimbursement paradigms create new pathways to sustain engagement and demonstrate value. Supply-chain and tariff pressures underscore the importance of operational resilience, yet they also incentivize strategic investments in regional capacity and diversified sourcing that can yield long-term stability.

In summary, success will hinge on coordinated action across product development, distribution, clinical training, and payer engagement. Stakeholders who proactively design integrated care models, invest in adherence-enabling technologies, and cultivate payer relationships anchored in real-world outcomes will be best positioned to improve patient trajectories and secure sustainable commercial performance. The pathway forward requires balanced attention to immediate operational risks and long-term clinical and economic value creation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of digital therapeutics and telehealth solutions in evidence-based alcohol use disorder treatment to improve patient outcomes
• 5.2. Rising adoption of AI-driven predictive analytics in mobile health apps to personalize alcohol craving management and relapse prevention
• 5.3. Emergence of long-acting injectable naltrexone and other advanced extended-release medications to enhance adherence in alcohol use disorder therapy
• 5.4. Rapid growth of telepsychiatry platforms enabling remote counseling and medication management for individuals with alcohol use disorder
• 5.5. Development of precision medicine strategies leveraging genetic and neurobiological biomarkers to tailor pharmacotherapy in alcohol use disorder
• 5.6. Increasing integration of virtual reality exposure therapy with cognitive behavioral counseling to address alcohol use disorder triggers more effectively
• 5.7. Expansion of employer-sponsored digital intervention programs incorporating remote monitoring and peer support for alcohol use disorder recovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alcohol Use Disorder Market, by Drug Class

• 8.1. Acamprosate
  • 8.1.1. Effervescent Tablet
  • 8.1.2. Oral Tablet
• 8.2. Disulfiram
  • 8.2.1. Oral Tablet
• 8.3. Naltrexone
  • 8.3.1. Injectable
  • 8.3.2. Oral Tablet

9. Alcohol Use Disorder Market, by Treatment Type

• 9.1. Behavioral Therapy
  • 9.1.1. Cognitive Behavioral Therapy
  • 9.1.2. Family Therapy
  • 9.1.3. Motivational Enhancement Therapy
• 9.2. Combined Therapy
  • 9.2.1. Cbt With Pharmacotherapy
  • 9.2.2. Met With Pharmacotherapy
• 9.3. Pharmacotherapy
  • 9.3.1. Injectable Drugs
  • 9.3.2. Oral Drugs

10. Alcohol Use Disorder Market, by End User

• 10.1. Home Healthcare
  • 10.1.1. Home Visits
  • 10.1.2. Telehealth
• 10.2. Hospitals
  • 10.2.1. Private Hospitals
  • 10.2.2. Public Hospitals
• 10.3. Rehabilitation Centers
  • 10.3.1. Inpatient
  • 10.3.2. Outpatient
• 10.4. Specialty Clinics
  • 10.4.1. Alcohol Rehabilitation Clinics
  • 10.4.2. Psychiatric Clinics

11. Alcohol Use Disorder Market, by Distribution Channel

• 11.1. Hospital Pharmacies
  • 11.1.1. Private Hospital Pharmacies
  • 11.1.2. Public Hospital Pharmacies
• 11.2. Online Pharmacies
  • 11.2.1. E-Commerce Websites
  • 11.2.2. Mobile Apps
• 11.3. Retail Pharmacies
  • 11.3.1. Chain Pharmacies
  • 11.3.2. Independent Pharmacies
• 11.4. Specialty Pharmacies
  • 11.4.1. Aud Specialty Pharmacies
  • 11.4.2. General Specialty Pharmacies

12. Alcohol Use Disorder Market, by Formulation

• 12.1. Dispersible Tablet
• 12.2. Effervescent Tablet
• 12.3. Injectable
  • 12.3.1. Intramuscular
  • 12.3.2. Intravenous
  • 12.3.3. Subcutaneous
• 12.4. Oral Tablet
  • 12.4.1. Immediate Release
  • 12.4.2. Sustained Release

13. Alcohol Use Disorder Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Alcohol Use Disorder Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Alcohol Use Disorder Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Alkermes plc
  • 16.3.2. H. Lundbeck A/S
  • 16.3.3. Teva Pharmaceutical Industries Ltd.
  • 16.3.4. Viatris Inc.
  • 16.3.5. Sandoz International GmbH
  • 16.3.6. Dr. Reddy's Laboratories Ltd.
  • 16.3.7. Sun Pharmaceutical Industries Ltd.
  • 16.3.8. Aurobindo Pharma Ltd.
  • 16.3.9. Lupin Limited
  • 16.3.10. Cipla Limited